Smoking Cessation Pipeline Highlights – 2017

Smoking Cessation Pipeline Highlights – 2017

  • January 2017 •
  • Report ID: 3895186 •
  • Format: PDF
The latest report from Fore Pharma, Smoking Cessation Pipeline Highlights – 2017, provides most up-to-date information on key pipeline products in the global Smoking Cessation market.

It covers emerging therapies for Smoking Cessation in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Smoking Cessation pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Smoking Cessation pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Smoking Cessation pipeline products by the company.

Short-term Launch Highlights:
Find out which Smoking Cessation pipeline products will be launched in the US and Ex-US till 2020.

SUMMARY:
- Smoking Cessation phase 3 clinical trial pipeline products
- Smoking Cessation phase 2 clinical trial pipeline products
- Smoking Cessation phase 1 clinical trial pipeline products
- Smoking Cessation preclinical research pipeline products
- Smoking Cessation discovery stage pipeline products
- Smoking Cessation pipeline products short-term launch highlights